Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). [electronic resource]
Producer: 20170814Description: 1009-1019 p. digitalISSN:- 1468-2060
- Administration, Oral
- Antirheumatic Agents -- therapeutic use
- Arthritis, Rheumatoid -- blood
- C-Reactive Protein -- metabolism
- Disability Evaluation
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Hemoglobins -- metabolism
- Humans
- Infections -- chemically induced
- Janus Kinase 1 -- antagonists & inhibitors
- Male
- Methotrexate -- therapeutic use
- Middle Aged
- Protein Kinase Inhibitors -- administration & dosage
- Pyridines -- administration & dosage
- Retreatment
- Severity of Illness Index
- Surveys and Questionnaires
- Treatment Outcome
- Triazoles -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.